175 related articles for article (PubMed ID: 12450701)
1. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.
Burkhard MJ; Valenski L; Leavell S; Dean GA; Tompkins WA
Vaccine; 2002 Dec; 21(3-4):258-68. PubMed ID: 12450701
[TBL] [Abstract][Full Text] [Related]
2. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
4. Feline immunodeficiency virus Gag- and Env-specific immune responses after vaginal versus intravenous infection.
Burkhard MJ; Mathiason CK; Bowdre T; Hoover EA
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1767-78. PubMed ID: 11788028
[TBL] [Abstract][Full Text] [Related]
5. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
6. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
[TBL] [Abstract][Full Text] [Related]
7. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
8. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
9. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
10. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
11. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
[TBL] [Abstract][Full Text] [Related]
12. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.
Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA
J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192
[TBL] [Abstract][Full Text] [Related]
13. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
[TBL] [Abstract][Full Text] [Related]
14. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.
Siebelink KH; Tijhaar E; Huisman RC; Huisman W; de Ronde A; Darby IH; Francis MJ; Rimmelzwaan GF; Osterhaus AD
J Virol; 1995 Jun; 69(6):3704-11. PubMed ID: 7745719
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
17. Interaction of acute feline herpesvirus-1 and chronic feline immunodeficiency virus infections in experimentally infected specific pathogen free cats.
Reubel GH; George JW; Barlough JE; Higgins J; Grant CK; Pedersen NC
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):95-119. PubMed ID: 1363011
[TBL] [Abstract][Full Text] [Related]
18. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
[TBL] [Abstract][Full Text] [Related]
19. Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats.
Gebhard DH; Dow JL; Childers TA; Alvelo JI; Tompkins MB; Tompkins WA
J Infect Dis; 1999 Nov; 180(5):1503-13. PubMed ID: 10515809
[TBL] [Abstract][Full Text] [Related]
20. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats.
Reubel GH; Dean GA; George JW; Barlough JE; Pedersen NC
J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1003-15. PubMed ID: 7916048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
